Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT ID: NCT02106546

Last Updated: 2020-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

970 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-10

Study Completion Date

2019-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Squamous Non-Small Cell Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

veliparib carboplatin paclitaxel Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP) Overall Survival Advanced Metastatic ABT-888 Squamous Randomized non-small cell lung cancer placebo controlled

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Veliparib + Carboplatin + Paclitaxel

Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.

Group Type EXPERIMENTAL

Carboplatin

Intervention Type DRUG

Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Veliparib

Intervention Type DRUG

Capsules taken orally twice a day, 12 hours apart.

Paclitaxel

Intervention Type DRUG

Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².

Placebo + Carboplatin + Paclitaxel

Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.

Group Type PLACEBO_COMPARATOR

Carboplatin

Intervention Type DRUG

Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Paclitaxel

Intervention Type DRUG

Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².

Placebo to veliparib

Intervention Type DRUG

Capsules taken orally twice a day, 12 hours apart.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carboplatin

Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.

Intervention Type DRUG

Veliparib

Capsules taken orally twice a day, 12 hours apart.

Intervention Type DRUG

Paclitaxel

Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².

Intervention Type DRUG

Placebo to veliparib

Capsules taken orally twice a day, 12 hours apart.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-888

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Life expectancy \> 12 weeks
2. Subject must have cytologically or histologically confirmed squamous NSCLC.
3. Subject must have advanced or metastatic squamous NSCLC that is not amenable to surgical resection or radiation with curative intent at time of study Screening.
4. Subjects with recurrent squamous NSCLC after surgical treatment that is not amenable to surgical resection or radiation with curative intent are eligible.
5. Subject must have at least 1 unidimensional measurable NSCLC lesion on a computerized tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version 1.1).

Exclusion Criteria

1. Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
2. Subject has a known hypersensitivity to platinum compounds.
3. Subject has peripheral neuropathy \>= grade 2.
4. Subject has non-squamous NSCLC, or a known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement.
5. Subject has received prior cytotoxic chemotherapy (including definitive chemoradiotherapy) for NSCLC, except for adjuvant or neoadjuvant therapy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AbbVie Inc.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northeast Arkansas Clinical Ch /ID# 128071

Jonesboro, Arkansas, United States

Site Status

LA Hem-Oncology Med Group /ID# 129178

Los Angeles, California, United States

Site Status

VA Eastern Colorado Healthcare System /ID# 128065

Aurora, Colorado, United States

Site Status

Holy Cross Hospital /ID# 128074

Fort Lauderdale, Florida, United States

Site Status

University of Florida - Archer /ID# 126476

Gainesville, Florida, United States

Site Status

Cancer Specialists of North Florida - Southpoint /ID# 127815

Jacksonville, Florida, United States

Site Status

Winship Cancer Institute of Emory University /ID# 124061

Atlanta, Georgia, United States

Site Status

St. Luke's Mountain States Tumor Institute - Boise /ID# 124059

Boise, Idaho, United States

Site Status

Illinois Cancer Specialists /ID# 127468

Arlington Heights, Illinois, United States

Site Status

NorthShore University HealthSystem - Evanston Hospital /ID# 128585

Evanston, Illinois, United States

Site Status

Ingalls Memorial Hosp /ID# 128360

Harvey, Illinois, United States

Site Status

Midwestern Regional CTC /ID# 126124

Zion, Illinois, United States

Site Status

Goshen Center for Cancer Care /ID# 123875

Goshen, Indiana, United States

Site Status

Franciscan St. Francis Health /ID# 126678

Indianapolis, Indiana, United States

Site Status

Appalachian Regional Healthcare, Inc (ARH) /ID# 128061

Hazard, Kentucky, United States

Site Status

Henry Ford Health System /ID# 126500

Detroit, Michigan, United States

Site Status

Sparrow Regional Cancer Center, Sparrow Health System /ID# 127156

Lansing, Michigan, United States

Site Status

Minnesota Oncology Hematology, PA /ID# 127473

Minneapolis, Minnesota, United States

Site Status

Nebraska Hematology Oncology /ID# 127699

Lincoln, Nebraska, United States

Site Status

SE Nebraska Hema/Oncology Consultants P.C.d/b/a Southeast Nebraska Cancer Center /ID# 126477

Lincoln, Nebraska, United States

Site Status

Comprehensive Cancer Ctrs Neva /ID# 127491

Las Vegas, Nevada, United States

Site Status

Dartmouth-Hitchcock Medical Center /ID# 128075

Lebanon, New Hampshire, United States

Site Status

Hackensack Univ Med Ctr /ID# 124057

Hackensack, New Jersey, United States

Site Status

Gabrail Cancer Center Research /ID# 127415

Canton, Ohio, United States

Site Status

Penn State University and Milton S. Hershey Medical Center /ID# 126676

Hershey, Pennsylvania, United States

Site Status

The Jones Clinic, PC /ID# 124062

Germantown, Tennessee, United States

Site Status

Texas Oncology - Austin Midtown /ID# 127477

Austin, Texas, United States

Site Status

Texas Oncology - South Austin /ID# 127476

Austin, Texas, United States

Site Status

Parkland Health and Hosp Syste /ID# 128518

Dallas, Texas, United States

Site Status

Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 128385

Dallas, Texas, United States

Site Status

UT Southwestern Medical Center /ID# 127876

Dallas, Texas, United States

Site Status

University of Texas MD Anderson Cancer Center /ID# 127946

Houston, Texas, United States

Site Status

Texas Oncology - Paris /ID# 127484

Paris, Texas, United States

Site Status

Texas Oncology - Waco /ID# 127459

Waco, Texas, United States

Site Status

University of Vermont Medical Center /ID# 128064

Burlington, Vermont, United States

Site Status

Virginia Oncology Associates /ID# 127458

Norfolk, Virginia, United States

Site Status

Northwest Cancer Specialists, P.C. /ID# 127486

Vancouver, Washington, United States

Site Status

Northwest Cancer Specialists, P.C. /ID# 127488

Vancouver, Washington, United States

Site Status

Southern Medical Day Care Ctr /ID# 125604

Wollongong, New South Wales, Australia

Site Status

Sunshine Coast University Hosp /ID# 125608

Birtinya, Queensland, Australia

Site Status

The Townsville Hospital /ID# 125609

Douglas, Queensland, Australia

Site Status

Flinders Centre for Innovation /ID# 125605

Bedford Park, South Australia, Australia

Site Status

The Queen Elizabeth Hospital /ID# 125607

Woodville, South Australia, Australia

Site Status

Barwon Health University Hospital Geelong /ID# 125606

Geelong, Victoria, Australia

Site Status

Ordensklinikum Linz GmbH, Elisabethinen /ID# 126183

Linz, , Austria

Site Status

Bobruysk Interdistrict Onco. /ID# 128999

Babruysk, , Belarus

Site Status

Brest Regional Hospital /ID# 125955

Brest, , Belarus

Site Status

State Institution Republican Scientific Practical Center of Oncology and Medica /ID# 125815

Lesnoy, , Belarus

Site Status

Mogilev Reg Clin Oncology Dis /ID# 128639

Mogilev, , Belarus

Site Status

Vitebsk Reg Clin Onc Disp /ID# 125516

Vitebsk, , Belarus

Site Status

Hospital Sao Lucas da PUCRS /ID# 127737

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Clinica de Neoplasias Litoral - Centro de Novos Tratamentos Itajai /ID# 127738

Itajaí, Santa Catarina, Brazil

Site Status

Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 126736

Barretos, São Paulo, Brazil

Site Status

Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 127309

Rio de Janeiro, , Brazil

Site Status

Instituto COI de Educacao e Pesquisa /ID# 127739

Rio de Janeiro, , Brazil

Site Status

Fundacao Antonio Prudente - AC Camargo Cancer Center /ID# 126737

São Paulo, , Brazil

Site Status

University of Calgary /Id# 126326

Calgary, Alberta, Canada

Site Status

Cross Cancer Institute /ID# 126154

Edmonton, Alberta, Canada

Site Status

Juravinski Cancer Clinic /ID# 126153

Hamilton, Ontario, Canada

Site Status

Victoria Hospital /ID# 126669

London, Ontario, Canada

Site Status

The Ottawa Hospital /ID# 126522

Ottawa, Ontario, Canada

Site Status

Princess Margaret Cancer Centre /ID# 126155

Toronto, Ontario, Canada

Site Status

McGill Univ HC /ID# 130431

Montreal, Quebec, Canada

Site Status

Iucpq-Ul /Id# 126524

Québec, Quebec, Canada

Site Status

CSSS Alphonse-Desjardins, CHAU de Levis /ID# 126149

Québec, Quebec, Canada

Site Status

Klinika za plucne bolesti Jordanovac /ID# 126537

Zagreb, City of Zagreb, Croatia

Site Status

Klinicki bolnicki centar Osijek /ID# 132214

Osijek, County of Osijek-Baranja, Croatia

Site Status

Opca bolnica Pula /ID# 126540

Pula, , Croatia

Site Status

Opca bolnica Dr. Josip Bencevi /ID# 126539

Slavonski Brod, , Croatia

Site Status

Fakultni Nemocnice Olomouc /ID# 125820

Olomouc, Olomoucký kraj, Czechia

Site Status

Nemocnice Na Plesi s.r.o. /ID# 125817

Nová Ves pod Pleší, Pribram, Czechia

Site Status

Nemocnice Kyjov, prispevkova organizace /ID# 125819

Kyjov, , Czechia

Site Status

Nemocnice Novy Jicin /ID# 125818

Nový Jičín, , Czechia

Site Status

Vitkovicka nemocnice a. s. /ID# 127023

Ostrava, , Czechia

Site Status

Herlev Hospital /ID# 125995

Herlev, Capital Region, Denmark

Site Status

Odense Universitets Hospital /ID# 125996

Odense C, Region Syddanmark, Denmark

Site Status

University of Alexandria /ID# 128337

Alexandria, , Egypt

Site Status

Naser Institute for Res & Dev /ID# 129263

Cairo, , Egypt

Site Status

Cairo Uni Hosp Al Kasr El Ainy /ID# 128338

Cairo, , Egypt

Site Status

Cairo Uni Hosp Al Kasr El Ainy /ID# 128340

Cairo, , Egypt

Site Status

North Estonian Medical Centre /ID# 128215

Tallinn, , Estonia

Site Status

Tartu University Hospital /ID# 127735

Tartu, , Estonia

Site Status

Helsinki Univ Central Hospital /ID# 125897

Helsinki, , Finland

Site Status

Vaasa Central Hospital /ID# 125896

Vaasa, , Finland

Site Status

CHU Hopital Nord /ID# 128388

Marseille, Bouches-du-Rhone, France

Site Status

Hopital Haut-Lévêque /ID# 135270

Pessac, Gironde, France

Site Status

CHRU Lille - Hôpital Claude Huriez /ID# 126353

Lille, Hauts-de-France, France

Site Status

Centre Hospitalier Le Mans /ID# 127902

Le Mans, Sarthe, France

Site Status

Centre Hosp Intercommunal de Creteil /ID# 125922

Créteil, Val-de-Marne, France

Site Status

CHRU de Brest - Hopital Morvan /ID# 127903

Brest, , France

Site Status

Centre Antoine Lacassagne /ID# 126360

Nice, , France

Site Status

Hospital Pontchaillou /ID# 126356

Rennes, , France

Site Status

Hopital Larrey - CHU de Toulouse /ID# 128394

Toulouse, , France

Site Status

Charite-Univ. Berlin, Benjamin-Franklin /ID# 125708

Berlin, , Germany

Site Status

Lungen Clinic Grosshansdorf /ID# 126107

Großhansdorf, , Germany

Site Status

Klinikum Kassel /ID# 127025

Kassel, , Germany

Site Status

Klinik Loewenstein GmbH /ID# 126191

Löwenstein, , Germany

Site Status

Univ Johannes Gutenberg /ID# 125603

Mainz, , Germany

Site Status

Papageorgiou General Hospital Thessaloniki /ID# 125876

Nea Efkarpia, Thessaloniki, Greece

Site Status

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 125879

Athens, , Greece

Site Status

Metropolitan Hospital /ID# 125878

Athens, , Greece

Site Status

University General Hospital of Heraklion PA.G.N.I /ID# 125877

Heraklion, , Greece

Site Status

CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 135234

Miskolc, Borsod-Abauj Zemplen county, Hungary

Site Status

Orszagos Koranyi Pulmonologiai Intezet /ID# 126112

Budapest XII, Budapest, Hungary

Site Status

Debreceni Egyetem Klinikai Központ /ID# 126119

Debrecen, , Hungary

Site Status

Veszprem Megyei Tudogyogyintez /ID# 126121

Farkasgyepű, , Hungary

Site Status

Petz Aladar Megyei Oktato Korh /ID# 126110

Győr, , Hungary

Site Status

Bekes Megyei Pandy Kalman Korhaz /ID# 126117

Gyula, , Hungary

Site Status

Matrahaza Gyogyintezet /ID# 126109

Kékesteto, , Hungary

Site Status

Fejer Megyei Szent Gyorgy Korh /ID# 126118

Székesfehérvár, , Hungary

Site Status

Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz /ID# 126120

Szolnok, , Hungary

Site Status

Tudogyogyintezet Toeroekbalint /ID# 126111

Törökbálint, , Hungary

Site Status

St. James's Hospital /ID# 126177

Dublin, Dublin, Ireland

Site Status

Cork University Hospital /ID# 126176

Cork, , Ireland

Site Status

Beaumont Hospital /ID# 126218

Dublin, , Ireland

Site Status

University Hospital Limerick /ID# 126175

Limerick, , Ireland

Site Status

University Hospital Waterford /ID# 126178

Waterford, , Ireland

Site Status

Assaf Harofeh Medical Center /ID# 127076

Be’er Ya‘aqov, , Israel

Site Status

Hadassah University Hospital /ID# 127077

Jerusalem, , Israel

Site Status

Meir Medical Center /ID# 127078

Kfar Saba, , Israel

Site Status

Sheba Medical Center /ID# 127079

Ramat Gan, , Israel

Site Status

AO San Giuseppe Moscati /ID# 125701

Avellino, , Italy

Site Status

Istituto Europeo di Oncologia /ID# 125702

Milan, , Italy

Site Status

Azienda Ospedaliera San Gerardo di Monza _ Oncologia Medica /ID# 125704

Monza, , Italy

Site Status

A.O.U. San Luigi Gonzaga /ID# 125700

Orbassano, , Italy

Site Status

Azienda Ospedaliero Uni Parma /ID# 125703

Parma, , Italy

Site Status

Azienda Ospedaliera-Universitaria di Perugia-Divisione di Oncologia Medica. /ID# 125699

Perugia, , Italy

Site Status

Istituto Oncologico del Medite /ID# 132844

Viagrande, , Italy

Site Status

Riga East Clinical Univ Hosp /ID# 125597

Riga, , Latvia

Site Status

P. Stradins Clinical Univ Hosp /ID# 126322

Riga, , Latvia

Site Status

Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 127176

Kaunas, Kaunas County, Lithuania

Site Status

National Cancer Institute /ID# 126323

Vilnius, , Lithuania

Site Status

Centro Estatal de Cancerologia /ID# 127583

Chihuahua City, , Mexico

Site Status

Cancerologia de Queretaro S.C. /ID# 125920

Querétaro City, , Mexico

Site Status

Hospital Angeles Centro Medico /ID# 127620

San Luis Potosí City, , Mexico

Site Status

Jeroen Bosch Ziekenhuis /ID# 125709

's-Hertogenbosch, , Netherlands

Site Status

Vrije Universiteit Medisch Centrum /ID# 125578

Amsterdam, , Netherlands

Site Status

Amphia Ziekenhuis /ID# 126466

Breda, , Netherlands

Site Status

Catharina Ziekenhuis /ID# 125577

Eindhoven, , Netherlands

Site Status

Ziekenhuis St. Jansdal /ID# 125576

Harderwijk, , Netherlands

Site Status

Atrium-Orbis Zuyderland Medisch Centrum /ID# 125710

Heerlen, , Netherlands

Site Status

Isala /ID# 125579

Zwolle, , Netherlands

Site Status

Wellington Hospital (Capital and Coast District Health Board) /ID# 125755

Wellington, , New Zealand

Site Status

Haukeland University Hospital /ID# 126338

Bergen, Hordaland, Norway

Site Status

Nordland Hospital /ID# 126337

Bodø, , Norway

Site Status

Sorlandet Sykehus HF /ID# 126341

Kristiansand, , Norway

Site Status

Oslo Universitetssykehus, Radiumhospitalet /ID# 126335

Oslo, , Norway

Site Status

Stavanger University Hospital /ID# 126336

Stavanger, , Norway

Site Status

Sykehuset i Vestfold HF /ID# 126340

Tønsberg, , Norway

Site Status

Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 126548

Rzeszów, Podkarpackie Voivodeship, Poland

Site Status

Szpital Morski im. PCK /ID# 126547

Gdynia, , Poland

Site Status

NZOZ Magodent Ctr. Med. Ostro /ID# 126545

Warsaw, , Poland

Site Status

Mazowiecki Szpital Onkologiczn /ID# 126546

Wieliszew, , Poland

Site Status

Hospital Senhora da Oliveira de Guimaraes, EPE /ID# 126761

Guimarães, Braga District, Portugal

Site Status

CCA Braga - Hospital de Braga /ID# 125837

Braga, , Portugal

Site Status

Ctr Hosp Univ Coimbra, EPE /ID# 125838

Coimbra, , Portugal

Site Status

Hospital Pulido Valente /ID# 125835

Lisbon, , Portugal

Site Status

IPO Porto FG, EPE /ID# 125836

Porto, , Portugal

Site Status

Centro Hospitalar de Sao Joao, EPE /ID# 125875

Porto, , Portugal

Site Status

VA Caribbean Healthcare System /ID# 124562

San Juan, , Puerto Rico

Site Status

Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 128458

Moscow, Moscow, Russia

Site Status

Sverdlovsk Regional Oncology Center Dispensary /ID# 128457

Yekaterinburg, Sverdlovsk Oblast, Russia

Site Status

Volgograd Regional Clinical Oncology Dispensary /ID# 126350

Volgograd, Volgograd Oblast, Russia

Site Status

Belgorod Oncology Dispensary /ID# 129899

Belgorod, , Russia

Site Status

State Budgetary Healthcare Institution"Irkutsk Regional Oncology Center /ID# 128460

Irkutsk, , Russia

Site Status

State Regional Budgetary Healthcare Institution " Murmansk Regional Oncology Dis /ID# 128461

Murmansk, , Russia

Site Status

Orenburg Regional Clinical Onc /ID# 137474

Orenburg, , Russia

Site Status

Ogarev Mordovia State Univ /ID# 127595

Saransk, , Russia

Site Status

Smolensk Regional Onc Clin Dis /ID# 127144

Smolensk, , Russia

Site Status

Cancer Research Institute Siberian Branch of the Russian Academy of Medical Scie /ID# 127143

Tomsk, , Russia

Site Status

Clinical Center Serbia /ID# 128738

Belgrade, Beograd, Serbia

Site Status

Clinical Center of Nis /ID# 128735

Niš, Nisavski Okrug, Serbia

Site Status

Institute for Oncology and Rad /ID# 128721

Belgrade, , Serbia

Site Status

University Hospital Bezanijska /ID# 128761

Belgrade, , Serbia

Site Status

Institute For Pulmonary Diseas /ID# 128737

Kamenitz, , Serbia

Site Status

Univerzitna Nemocnica Bratislava /ID# 126342

Bratislava, , Slovakia

Site Status

MEDEON, s.r.o. /ID# 128517

Pieštany, , Slovakia

Site Status

GVI Oncology /ID# 126102

Port Elizabeth, Eastern Cape, South Africa

Site Status

Wits Clinical Research Site /ID# 126101

Johannesburg, Gauteng, South Africa

Site Status

Sandton Oncology Centre /ID# 126097

Johannesburg, Gauteng, South Africa

Site Status

University of Pretoria /ID# 127297

Pretoria, Gauteng, South Africa

Site Status

Dr Albert, Bouwer and Jordaan Incorporated /ID# 126098

Pretoria, Gauteng, South Africa

Site Status

Mary Potter Oncology Centre /ID# 126099

Pretoria, Gauteng, South Africa

Site Status

The Oncology Centre /ID# 126096

Durban, KwaZulu-Natal, South Africa

Site Status

Netcare Oncology Intervent Ctr /ID# 126100

Cape Town, Western Cape, South Africa

Site Status

Cancercare Outeniqua Oncology Unit /ID# 126103

George, Western Cape, South Africa

Site Status

Hospital Duran i Reynals /ID# 125161

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital Universitario Puerta de Hierro Majadahonda /ID# 125160

Majadahonda, Madrid, Spain

Site Status

Hospital Universitario Vall d'Hebron /ID# 125159

Barcelona, , Spain

Site Status

Hospital Universitario HM Sanchinarro /ID# 125162

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio /ID# 125207

Seville, , Spain

Site Status

Fundacion Instituto Valenciano Oncologia IVO /ID# 125205

Valencia, , Spain

Site Status

Gavle Sjukhus /ID# 126444

Gävle, , Sweden

Site Status

Sahlgrenska University Hosp /ID# 129997

Gothenburg, , Sweden

Site Status

University Hospital Linkoping /ID# 126443

Linköping, , Sweden

Site Status

Karolinska Univ Sjukhuset /ID# 126445

Solna, , Sweden

Site Status

Kantonsspital St. Gallen /ID# 126349

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status

Hirslanden Medical Center /ID# 128216

Aarau, , Switzerland

Site Status

Inselspital, Universitaetsklinik /ID# 126347

Bern, , Switzerland

Site Status

Spital STS AG /ID# 126348

Thun, , Switzerland

Site Status

Akdeniz University Medical Fac /ID# 126997

Antalya, , Turkey (Türkiye)

Site Status

Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 126186

Istanbul, , Turkey (Türkiye)

Site Status

Marmara University Medical Fac /ID# 126187

Istanbul, , Turkey (Türkiye)

Site Status

Ege University Medical Faculty /ID# 126189

Izmir, , Turkey (Türkiye)

Site Status

Dr. Suat Seren Gogus Has /ID# 126190

Izmir, , Turkey (Türkiye)

Site Status

Communal non-profit enterprise Regional Center of Oncology /ID# 128221

Kharkiv, Kharkivs’ka Oblast’, Ukraine

Site Status

Cherkassy Regional Onc Ctr /ID# 128222

Cherkasy, , Ukraine

Site Status

Regional Municipal Non-Profit Enterprise Bukovynian Clinical Oncology Center /ID# 128220

Chernivtsi, , Ukraine

Site Status

Municipal Non-Profit Enterprise City Clinical Hospital No.4 of Dnipro City Counc /ID# 128217

Dnipro, , Ukraine

Site Status

Lviv Oncological Regional Therapeutical and Diagnostic Centre /ID# 128218

Lviv, , Ukraine

Site Status

Poltava Regional Clinical Oncology Centre of Poltava Regional Council /ID# 128223

Poltava, , Ukraine

Site Status

Municipal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical /ID# 128219

Sumy, , Ukraine

Site Status

Cheltenham General Hospital /ID# 125692

Cheltenham, Gloucestershire, United Kingdom

Site Status

Guy's and St Thomas' NHS Found /ID# 125694

London, London, City of, United Kingdom

Site Status

Norfolk and Norwich Univ Hosp /ID# 125697

Norwich, Norfolk, United Kingdom

Site Status

Betsi Cadwaladr Univ Health Bo /ID# 127177

Bangor, , United Kingdom

Site Status

North Devon District Hospital /ID# 125689

Barnstaple, , United Kingdom

Site Status

The Royal Bournemouth Hospital /ID# 125690

Bournemouth, , United Kingdom

Site Status

East Kent Hosp Univ NHS Trust /ID# 125698

Canterbury, , United Kingdom

Site Status

Gartnavel General Hospital /ID# 126233

Glasgow, , United Kingdom

Site Status

James Paget University Hosp /ID# 125696

Great Yarmouth, , United Kingdom

Site Status

Charing Cross Hospital /ID# 125688

London, , United Kingdom

Site Status

Maidstone Hospital /ID# 125693

Maidstone, , United Kingdom

Site Status

The Clatterbridge Cancer Ctr /ID# 125695

Metropolitan Borough of Wirral, , United Kingdom

Site Status

The Newcastle Upon Tyne Hospitals NHS Foundation Trust Freeman Hospital /ID# 129228

Newcastle upon Tyne, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belarus Brazil Canada Croatia Czechia Denmark Egypt Estonia Finland France Germany Greece Hungary Ireland Israel Italy Latvia Lithuania Mexico Netherlands New Zealand Norway Poland Portugal Puerto Rico Russia Serbia Slovakia South Africa Spain Sweden Switzerland Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 Nov 10;39(32):3633-3644. doi: 10.1200/JCO.20.03318. Epub 2021 Aug 26.

Reference Type DERIVED
PMID: 34436928 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-005020-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M11-089

Identifier Type: -

Identifier Source: org_study_id